COVID-19 and Candida duobushaemulonii superinfection: A case report
| dc.contributor.author | Awada, Bassem | |
| dc.contributor.author | Alam, Walid | |
| dc.contributor.author | Chalfoun, Maria | |
| dc.contributor.author | Araj, George F. | |
| dc.contributor.author | Bizri, Abdul Rahman N. | |
| dc.contributor.department | Internal Medicine | |
| dc.contributor.department | Division of Health Professions | |
| dc.contributor.faculty | Faculty of Medicine (FM) | |
| dc.contributor.faculty | Faculty of Health Sciences (FHS) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T12:01:33Z | |
| dc.date.available | 2025-01-24T12:01:33Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Introduction: Critically ill COVID-19 patients are at high risk for nosocomial bacterial and fungal infections due to several predisposing factors such as intensive care unit stay, mechanical ventilation, and broad-spectrum antibiotics. Data regarding multidrug resistant (MDR) Candida species in COVID-19 patients is scarce, and nonexistent regarding Candida duobushaemulonii superinfections. Case description: A 34-year-old male presented to our institution with acute respiratory distress syndrome (ARDS) due to COVID-19 infection and developed Candida duobushaemulonii fungemia after multiple courses of antibiotics and prolonged mechanical ventilation. He died after recurrent pneumothorax led to respiratory failure and cardiac arrest. Discussion: Bacterial and fungal infections are common complications of viral pneumonia in critically ill patients. Data regarding these infections in COVID-19 patients has been poorly studied with only a few cases reporting secondary infection, mostly without identifying specific pathogens. Prolonged hospital stays, invasive interventions (central venous catheter, mechanical ventilation), and the use of broad-spectrum antibiotics in COVID-19 infections could carry a high risk of bacterial and/or fungal superinfections. Conclusion: Strategies to improve outcome in COVID-19 ICU patients should include early recognition of candidemia and appropriate antifungal therapy. © 2021 SFMM | |
| dc.identifier.doi | https://doi.org/10.1016/j.mycmed.2021.101168 | |
| dc.identifier.eid | 2-s2.0-85111074620 | |
| dc.identifier.pmid | 34186378 | |
| dc.identifier.uri | http://hdl.handle.net/10938/31456 | |
| dc.language.iso | en | |
| dc.publisher | Elsevier Masson s.r.l. | |
| dc.relation.ispartof | Journal of Medical Mycology | |
| dc.source | Scopus | |
| dc.subject | Broad-spectrum antibiotics | |
| dc.subject | Candida duobushaemulonii | |
| dc.subject | Covid-19 | |
| dc.subject | Icu | |
| dc.subject | Mechanical ventilation | |
| dc.subject | Multidrug resistance | |
| dc.subject | Adult | |
| dc.subject | Antifungal agents | |
| dc.subject | Candida | |
| dc.subject | Candidemia | |
| dc.subject | Fatal outcome | |
| dc.subject | Humans | |
| dc.subject | Male | |
| dc.subject | Respiration, artificial | |
| dc.subject | Respiratory distress syndrome | |
| dc.subject | Saccharomycetales | |
| dc.subject | Superinfection | |
| dc.subject | Alteplase | |
| dc.subject | Amikacin | |
| dc.subject | Amphotericin b | |
| dc.subject | Avibactam plus ceftazidime | |
| dc.subject | C reactive protein | |
| dc.subject | Carbapenem derivative | |
| dc.subject | Caspofungin | |
| dc.subject | Colistin | |
| dc.subject | Cotrimoxazole | |
| dc.subject | D dimer | |
| dc.subject | Ferritin | |
| dc.subject | Fluconazole | |
| dc.subject | Flucytosine | |
| dc.subject | Imipenem | |
| dc.subject | Levofloxacin | |
| dc.subject | Meropenem | |
| dc.subject | Tigecycline | |
| dc.subject | Voriconazole | |
| dc.subject | Antifungal agent | |
| dc.subject | Adult respiratory distress syndrome | |
| dc.subject | Antibiotic resistance | |
| dc.subject | Antibiotic sensitivity | |
| dc.subject | Antifungal therapy | |
| dc.subject | Article | |
| dc.subject | Artificial ventilation | |
| dc.subject | Bacterial pneumonia | |
| dc.subject | Candida parapsilosis | |
| dc.subject | Case report | |
| dc.subject | Catheter infection | |
| dc.subject | Clavispora lusitaniae | |
| dc.subject | Clinical article | |
| dc.subject | Computer assisted tomography | |
| dc.subject | Coronavirus disease 2019 | |
| dc.subject | Death | |
| dc.subject | Drug substitution | |
| dc.subject | Drug withdrawal | |
| dc.subject | Enterobacter cloacae | |
| dc.subject | Heart arrest | |
| dc.subject | Human | |
| dc.subject | Hypotension | |
| dc.subject | Intensive care unit | |
| dc.subject | Intubation | |
| dc.subject | Lung embolism | |
| dc.subject | Minimum inhibitory concentration | |
| dc.subject | Neutrophilia | |
| dc.subject | Pneumothorax | |
| dc.subject | Polymerase chain reaction | |
| dc.subject | Respiratory failure | |
| dc.subject | Sedation | |
| dc.subject | Septic shock | |
| dc.subject | Severe acute respiratory syndrome coronavirus 2 | |
| dc.subject | Stenotrophomonas maltophilia | |
| dc.subject | Subarachnoid hemorrhage | |
| dc.subject | Thrombocytosis | |
| dc.subject | Urinary tract infection | |
| dc.subject | Urine culture | |
| dc.subject | Ventilator associated pneumonia | |
| dc.subject | Budding yeast | |
| dc.subject | Complication | |
| dc.subject | Fatality | |
| dc.title | COVID-19 and Candida duobushaemulonii superinfection: A case report | |
| dc.type | Article |
Files
Original bundle
1 - 1 of 1